Expression of the SART-1 tumor rejection antigen in Breast
| Project/Area Number |
10671143
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
KOGA Toshihiro KURUME Univ., Sch. Med., Lecturer, 医学部, 講師 (40186648)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHICHIJO Shigeki KURUME Univ., Sch. Med., Assistant Professor, 医学部, 助教授 (30080592)
KAWAMOTO Mayumi KURUME Univ., Sch. Med., Assistant, 医学部, 助手 (40289377)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1999: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | breast cancer / SART-1 |
|---|
| Research Abstract |
We investigated in breast cancers the expression of the SART-1 gene encoding tumor rejection antigens. SART-1 mRNA was expressed in all of the samples tested. The SART-l antigen was detectable in 20 of 50 (40%) breast cancer tissues and all breast cancer cell line tested, but not in normal breast tissues. The SART-1 breast cancer cells transfected with HLA-A2601 or HLA-A2402 cDNA were recognized by the HLA-A26-restricted and SART-1 specific cytotoxic T lymphocytes (CTLs) or the HLA-A24-restricted and SART-1-speciflC CTLs, respectively. Among the 20 SART-1 tumors, 9 or 8 tumors expressed estrogen receptor or progesterone receptor, respectively. Therefore, the patients with HLA-A26 or -A24 haplotype might be appropriate candidates for specific immunotherapy with the SART-1 peptides independently or in combination with hormone therapy.
|
Report
(3 results)
Research Products
(4 results)
